The objective of this contract is to understand the human mucosal immune response generated by infection or vaccination with enteric bacteria and viruses. This information is needed in order to develop effective vaccination strategies against enteric pathogens. The contractor will employ studies of human adult volunteers to accomplish the objectives of the contract. Individuals will be challenged with genetically weakened (attenuated) or wild-type Escherichia coli, Salmonella species, Shigella species, Vibrio cholerae, Campylobacter species, Helicobacter pylori, rotavirus, other enteric viruses, or other appropriate organisms. Their immune response to such challenge will be extensively characterized in order to identify those aspects of the immune response that correlate with protection from challenge by wild-type organisms. Once identified, further efforts will be made through iterative methodology to maximize that protective aspect of the immune response through the use of various adjuvants, delivery systems, dosing schedules or other methods. The contractor will recruit adult volunteers from the Baltimore/Washington metropolitan community, screen them for appropriate immune status, instruct them about the nature of the study and its objectives, perform the studies on an isolation ward in the hospital or in out-patients when appropriate, and provide the necessary follow-up and treatment for all volunteers. It is further intended that the contractor will interact effectively and frequently with a second contractor working on equivalent studies of respiratory pathogens (Baylor College of Medicine, N01-AI-65298). It is anticipated that synergistic effects will be achieved by these two groups in the furthering of our understanding of the human mucosal immune response. Such a result will likely benefit studies of diseases other than those associated with the digestive or respiratory systems. It is anticipated that these studies will lead to more effective vaccine strategies against a large number of infectious diseases.

Project Start
1996-01-22
Project End
2003-01-21
Budget Start
1998-09-23
Budget End
2000-01-21
Support Year
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Type
Other Domestic Higher Education
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Wahid, Rezwanul; Pasetti, Marcela F; Maciel Jr, Milton et al. (2011) Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. Clin Immunol 138:187-200
Kavanagh, Owen V; Ajami, Nadim J; Cheng, Elly et al. (2010) Rotavirus enterotoxin NSP4 has mucosal adjuvant properties. Vaccine 28:3106-11
Tacket, C O (2009) Plant-based oral vaccines: results of human trials. Curr Top Microbiol Immunol 332:103-17
Wahid, R; Salerno-Goncalves, R; Tacket, C O et al. (2008) Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue- homing potential by oral attenuated CVD 909 typhoid vaccine in humans. Mucosal Immunol 1:389-98
Tarr, Cheryl L; Nelson, Adam M; Beutin, Lothar et al. (2008) Molecular characterization reveals similar virulence gene content in unrelated clonal groups of Escherichia coli of serogroup O174 (OX3). J Bacteriol 190:1344-9
Lombardo, Mary-Jane; Michalski, Jane; Martinez-Wilson, Hector et al. (2007) An in vivo expression technology screen for Vibrio cholerae genes expressed in human volunteers. Proc Natl Acad Sci U S A 104:18229-34
Wahid, Rezwanul; Salerno-Goncalves, Rosangela; Tacket, Carol O et al. (2007) Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine 25:1416-25
Tacket, Carol O (2007) Plant-based vaccines against diarrheal diseases. Trans Am Clin Climatol Assoc 118:79-87
Dowling, Thomas C; Chavaillaz, Pierre A; Young, David G et al. (2005) Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. Antimicrob Agents Chemother 49:1808-12
Tacket, Carol O (2005) Plant-derived vaccines against diarrheal diseases. Vaccine 23:1866-9

Showing the most recent 10 out of 25 publications